Literature DB >> 19029911

Asymmetric RNA duplexes mediate RNA interference in mammalian cells.

Xiangao Sun1, Harry A Rogoff, Chiang J Li.   

Abstract

RNA interference (RNAi) has become an indispensable technology for biomedical research and has demonstrated the potential to become a new class of therapeutic. Current RNAi technology in mammalian cells relies on short interfering RNA (siRNA) consisting of symmetrical duplexes of 19-21 base pairs (bp) with 3' overhangs. Here we report that asymmetric RNA duplexes with 3' and 5' antisense overhangs silence mammalian genes effectively. An asymmetric interfering RNA (aiRNA) of 15 bp was incorporated into the RNA-induced silencing complex (RISC) and mediated sequence-specific cleavage of the target mRNA between base 10 and 11 relative to the 5' end of the antisense strand. The gene silencing mediated by aiRNA was efficacious, durable and correlated with reduced off-target silencing by the sense strand. These results establish aiRNA as a scaffold structure for designing RNA duplexes to induce RNAi in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029911     DOI: 10.1038/nbt.1512

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  44 in total

Review 1.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

Review 2.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

3.  Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing.

Authors:  Pooja Dua; Jae Wook Yoo; Soyoun Kim; Dong-ki Lee
Journal:  Mol Ther       Date:  2011-06-14       Impact factor: 11.454

Review 4.  Structural diversity repertoire of gene silencing small interfering RNAs.

Authors:  Chan Il Chang; Helena Andrade Kim; Pooja Dua; Soyoun Kim; Chiang J Li; Dong-ki Lee
Journal:  Nucleic Acid Ther       Date:  2011-06       Impact factor: 5.486

5.  Single-stranded microRNA mimics.

Authors:  Guillaume Chorn; Molly Klein-McDowell; Lihong Zhao; Matthew A Saunders; W Michael Flanagan; Aarron T Willingham; Lee P Lim
Journal:  RNA       Date:  2012-08-21       Impact factor: 4.942

Review 6.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

7.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

8.  Selection and optimization of asymmetric siRNA targeting the human c-MET gene.

Authors:  Seul-gi Jo; Sun Woo Hong; Jae Wook Yoo; Chang Han Lee; Sera Kim; Soyoun Kim; Dong-ki Lee
Journal:  Mol Cells       Date:  2011-11-03       Impact factor: 5.034

Review 9.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

Review 10.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.